Skip to main content

Aldeyra Therapeutics Inc

For the period ended Dec 31, 2023. Filed Mar 7, 2024.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 7, 2024

ALDX$0.63-1.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Consolidated Balance Sheets at December 31, 2023 and 2022

December 31,December 31,
20232022
ASSETS
Current assets:
Cash and cash equivalents$142,823,016$144,419,364
Marketable securities—29,881,520
Prepaid expenses and other current assets4,987,3176,722,229
Total current assets147,810,333181,023,113
Fixed assets, net5,76419,279
Right-of-use assets510,814249,265
Total assets$148,326,911$181,291,657
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable$1,338,057$133,625
Accrued expenses5,536,46414,065,885
Current portion of long-term debt15,146,546911,763
Operating lease liabilities239,183249,265
Total current liabilities22,260,25015,360,538
Deferred collaboration revenue, long-term6,000,000—
Operating lease liabilities, long-term271,631—
Long-term debt, net of current portion—14,923,090
Total liabilities28,531,88130,283,628
Commitments and contingencies (Notes 3, 9, & 13)
Stockholders' equity:
Preferred stock, $0.001 par value, 15,000,000 shares authorized, none issued and outstanding——
Common stock, voting, $0.001 par value; 150,000,000 authorized and 59,195,951 and 58,560,078 shares issued and outstanding, respectively59,19658,560
Additional paid-in capital513,994,982507,770,045
Accumulated other comprehensive loss—(103,938)
Accumulated deficit(394,259,148)(356,716,638)
Total stockholders’ equity119,795,030151,008,029
Total liabilities and stockholders’ equity$148,326,911$181,291,657
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.